Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30results about How to "Inhibit cell migration" patented technology

Multi-stage collagen-based template or implant for use in the repair of cartilage lesions

The invention is a template to aid in the regeneration of articular cartilage. The template is formed by combining a porous collagen sponge ("collagen matrix") with a dense collagen membrane. The dense collagen membrane is placed on the surface of the cartilage defect to prevent cell migration from the subchondral plate and vasculature. The collagen membrane will allow movement and exchange of fluids, nutrients, cytokines and other factors necessary for cartilage regeneration. The collagen matrix has been developed to allow attachment and growth of cells, specifically chondrocytes which are normally found in articular cartilage. The collagen matrix can be combined with chondrocytes in vitro, and therefore serve to transport cultured cells to the defect site and to retain the cells in position following implantation. Procedures are described to effectively use the two-staged template, and to fix the template to the repair site.
Owner:HOSPITAL FOR JOINT DISEASES ORTHOPEDIC INST

Endovascular implant for the injection of an active substance into the media of a blood vessel

InactiveUS20050027350A1Low production costAlocal side-effects are very substantially excludedHeart valvesBlood vesselsBiomedical engineeringVascular wall
The invention concerns an endovascular implant for the application of an active substance into the media 22 of a blood vessel and two processes for the production thereof. A base body 42 of the implant has at least in portion-wise manner at a surface 40 which is towards the blood vessel, a plurality of microdevices 10 for injection of the active substance. Each microdevice 10 includes on the one hand at least one microcannula 38 which is raised out of the surface 40 of the implant to such an extent that, when the implant bears against a wall 12 of the blood vessel in surface contact, the microcannula penetrates into the media 22 of the blood vessel, and on the other hand at least one active substance deposit 36 which is in communication with at least one microcannula 38.
Owner:BIOTRONIK

Inhibition Of Superoxide Dismutase By Tetrathiomolybdate: Identification Of New Anti-Angiogenic And Antitumor Agents

Though copper is elevated in the tumor tissue and plasma of patients with various malignancies, the molecular targets for copper binding agents in angiogenesis and tumor progression remain poorly understood. It is disclosed that one anti-angiogenic target for the copper binding agent tetrathiomolybdate is intracellular CuZn-superoxide dismutase (SOD1). A second generation tetrathiomolybdate analog, ATN-224, inhibits endothelial cell (EC) proliferation in vitro, binds to SOD1 and inhibits its activity without displacing bound copper ATN-224 can accumulate in ECs and inhibit CuZnSOD activity with an IC50 similar to the IC50 for EC proliferation, resulting in increased generation of intracellular reactive oxygen species. Inhibition of EC proliferation by ATN-224 in vitro is substantially reversed by a synthetic porphyrin SOD mimetic. Similar results were observed in vivo, where inhibition of angiogenesis by ATN-224 in a Matrigel plug model was also reversed by MnTBAP. Thus, a distinct molecular target for copper depletion therapy has been identified and SOD1 is now validated as a target for anti-angiogenesis. Methods for screening, or designing, such SOD1 inhibitors for use as angiogenesis inhibitors and anti-cancer agents are disclosed.
Owner:ATTENUON LLC

Application of IGFL4 gene as marker in diagnosis and treatment of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer

The invention relates to the technical field of molecular biology and tumor marker medicine, in particular to application of an IGFL4 gene as a marker in diagnosis and treatment of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer. The IGFL4 gene can be used as a diagnostic biomarker for gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer or can be used for preparing a cancer diagnosis product. The IGFL4 gene is specifically overexpressed in gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, but there is no such specific high expression in normal tissues. By detecting IGFL4 gene expression in a subject, occurrence of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer can be quickly, accurately and clearly determined. The IGFL4 gene serves as a diagnostic marker of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, provides a new target for clinical treatment of gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, and can be applied to preparation of antitumor drugs.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY

Application of KLC3 gene as marker in diagnosis and treatment of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer

The invention relates to the technical field of molecular biology and tumor marker medicine, in particular to application of a KLC3 gene as a marker in diagnosis and treatment of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer. The KLC3 gene can be used as a diagnostic biomarker for lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer or can be used for preparing a cancer diagnosis product. The KLC3 gene is specifically overexpressed in lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, but there is no such specific high expression in normal tissues. By detecting the expression of the KLC3 gene in a subject, the occurrence of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer can be quickly, accurately and clearly determined. The KLC3 gene serves as a diagnostic marker of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, provides a new target for clinical treatment of lung cancer, gastric cancer, colorectal cancer, endometrial cancer and ovarian cancer, and can be applied to preparation of antitumor drugs.
Owner:THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY

TRPM2-specfic inhibitors

The present invention relates to methods and compositions for modulating ADPR-mediated migratory activity of cells through regulation of the TRPM2 cation channel. Such methods and compositions may be used for the treatment of disorders including, but not limited to, inflammation, ischemia, atherosclerosis, asthma, autoimmune disease, diabetes, arthritis, allergies, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages, monocytes and dendritic cells. The invention further relates to specific inhibition of TRPM2 by blocking the activity of ADPR. The invention also relates to drug screening assays designed to identify compounds that regulate TRPM2 and thereby also function to modulate ADPR-mediated cell migration. The invention is based on the discovery that, 8Br-ADPR, which specifically inhibits activation of TRPM2, acts to inhibit ADPR-mediated cell migration.
Owner:RGT UNIV OF MINNESOTA +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products